McKesson Jumps on Contract Extension, But Overvaluation Risks Remain

What happened

McKesson shares jumped over 5% after the company announced an existing arrangement has been extended through June 2032 and reaffirmed its fiscal 2026 guidance. The news was interpreted as a positive signal of continued partnership stability, reinforcing the company's growth outlook. However, the DeepValue master report cautions that McKesson's valuation already embeds high expectations, trading at roughly 32.6x trailing GAAP EPS, leaving limited margin of safety. Furthermore, the report highlights that recent growth has been partly acquisition-aided and boosted by one-time gains, while opioid litigation risks remain a significant overhang. Therefore, while the contract extension provides incremental visibility, it does not resolve the core concerns of overvaluation and earnings quality, supporting a cautious stance on new positions at elevated levels.

Implication

Investors should view the contract extension as a supportive but non-transformative event that provides revenue visibility through 2032. At the current elevated valuation, the stock's risk-reward profile remains skewed to the downside, with the base-case fair value estimate of $760 implying meaningful potential loss from recent levels. The reaffirmed guidance is reassuring, but the company's EPS growth has been aided by acquisitions and one-time items, raising questions about the sustainability of organic growth. Opioid litigation remains a wildcard, with the revived West Virginia lawsuit potentially adding billions in liabilities that could pressure capital returns. Accordingly, we recommend a disciplined approach: trim positions above $880, wait for a pullback toward $720 before adding, and monitor quarterly results for signs of organic growth in Oncology & Multispecialty.

Thesis delta

The contract extension through June 2032 provides incremental long-term revenue stability but does not materially alter our investment thesis. McKesson remains overvalued relative to the quality of organic earnings growth, with heavy reliance on acquisitions and buybacks. The reaffirmed guidance and positive stock reaction do not offset the legal overhang and margin pressure risks that underpin our 'Potential Sell' rating.